Back to results
US 2025/0144245 A1Published application
Gene therapy for arrhythmogenic cardiomyopathy
AssigneeGinkgo Bioworks, Inc.
InventorsJohn Graef, Chicheng Sun
Life of this patent
Estimating the term…
Abstract
The disclosure provides nucleic acids (comprising AAV expression cassettes), AAV vectors, and compositions for use in methods for treating and/or delaying the onset of diseases associated with mutations in genes, such as PKP2, associated with arrhythmogenic cardiomyopathy. Also, provided herein are methods for treating and/or delaying the onset of arrhythmogenic cardiomyopathy.
Claims82
A nucleic acid molecule, comprising an adeno-associated virus (AAV) expression cassette, wherein the AAV expression cassette comprises, from 5′ to 3′:
- (i) a 5′ AAV inverted terminal repeat (ITR);
- (ii) a promoter;
- (iii) an arrhythmogenic cardiomyopathy-associated transgene;
- and
- (iv) a 3′ AAV ITR.
2 more elements
Dependencies are inferred from the claim text.